The full-fledged administration of Kymriah, a Korean Novartis CAR-T treatment called an "ultra-high-priced anticancer drug," has begun. Hospitals have also become busy as the administration of treatments at four large hospitals in Korea has begun in earnest. At the beginning of last year's domestic approval, it was a wait-and-see attitude, but as the number of inquiries from patients increased at the same time as the benefit increased, it is eager to complete the facility.

According to the medical community, starting with Asan Medical Center in Seoul, Kyungpook National University Hospital, Chonnam National University Hospital, and Pusan National University Hospital are currently undergoing preliminary